The duo comprised of clinical-stage natural psilocybin biotech Psyence Group Inc. and special purpose acquisition company Newcourt Acquisition Corp (NASDAQ:NCAC) announced that the SEC made effective a Form F-4 registration statement for a new business on November 13.
Psyence Group's CEO, Dr Neil Maresky says receiving SEC's effectiveness is "one step closer to a listing on a U.S. national security exchange" and enhances the company's corporate profile while it aims to launch a Phase 2b clinical trial on nature-derived psilocybin in palliative care.
Filed by new public company Psyence Biomedical Ltd., the statement is linked to an announced business combination between Newcorp and Psyence's wholly-owned subsidiary, Psyence Biomed Corp, valued at $50 million in pre-money equity.
Specifically, Psyence will contribute its therapeutics division to the new public company, to become a reporting issuer in the U.S. Expected to close within two business days following satisfaction of the requisite closing conditions and approvals contained in the agreement, the new company's common shares are anticipated to trade under the Nasdaq ticker "PBM".
Stock Option Plan, Participants & Advisors
Under a stock option plan, Psyence Group has granted stock options to eligible participants for the purchase of an aggregate 6,104,043 of its common shares at an exercise price of $0.043 (CA$0.06) per share.
Of those, 3,887,377 options would expire on Dec. 31, 2025; 1,800,000 on June 30, 2026; and 416,666 on Dec. 31, 2027.
Newcourt, Psyence and other parties to the amended and restated business combination agreement, and their respective directors and executive officers, other members of management and employees may be considered participants in the solicitation of proxies on the potential transaction under SEC rules.
Information on Newcourt's directors and executive officers can be found in the company's SEC filings. Information regarding other potential participants in the shareholders' solicitation, in connection with the transaction, and a description of their interests will be set forth in the registration statement when filed with the SEC.
Psyence's advisors are Maxim Group LLC (financial,) WeirFoulds LLP, Ellenoff Grossman & Schole LLP (legal, Canadian and U.S. respectively.) Newcourt's U.S. legal advisor is McDermott Will & Emery.
由臨床階段的天然迷幻藥生物技術公司Psyence Group Inc.和特殊目的收購公司Newcourt Acquisition Corp(納斯達克股票代碼:NCAC)組成的二人組宣佈,美國證券交易委員會於11月13日對一項新業務的F-4表格註冊聲明生效。
Psyence Group首席執行官尼爾·馬雷斯基博士表示,獲得美國證券交易委員會的有效性 “離在美國國家證券交易所上市又近了一步”,並提高了該公司的企業知名度,同時其目標是啓動一項針對姑息治療中自然衍生的迷幻藥的2b期臨床試驗。
該聲明由新的上市公司Psyence Biomedical Ltd.提交,與Newcorp與Psyence的全資子公司Psyence Biomed Corp宣佈的業務合併有關,後者的預付股權爲5000萬美元。
具體而言,Psyence將向這家新的上市公司捐贈其治療部門,使其成爲美國的報告發行人。預計新公司的普通股將在滿足協議中規定的必要成交條件和批准後的兩個工作日內關閉,預計將在納斯達克股票代碼 “PBM” 下交易。
股票期權計劃、參與者和顧問
根據股票期權計劃,Psyence Group已向符合條件的參與者授予股票期權,以每股0.043美元(0.06加元)的行使價購買總計6,104,043股普通股。
其中,3,887,377份期權將於2025年12月31日到期;1800,000份期權將於2026年6月30日到期;416,666份期權將於2027年12月31日到期。
根據美國證券交易委員會的規定,Newcourt、Psyence和經修訂和重述的業務合併協議的其他各方及其各自的董事和執行官、其他管理層成員和員工,可以被視爲潛在交易徵集代理人的參與者。
有關紐考特董事和執行官的信息可以在該公司向美國證券交易委員會提交的文件中找到。向美國證券交易委員會提交的註冊聲明中將列出與該交易有關的其他潛在股東招標參與者的信息及其利益描述。
Psyence的顧問是Maxim Group LLC(金融)、WeirFoulds LLP、Ellenoff Grossman & Schole律師事務所(分別爲法律、加拿大和美國)。紐考特的美國法律顧問是麥克德莫特·威爾和埃默裏。
照片:Benzinga 在 Pixabay 上編輯,照片由傑拉特和謝爾蓋托克馬科夫拍攝。